BioSpace News Archive

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies

Sonex Health and the Institute of Advanced Ultrasound Guided Procedures have announced they are hosting the first annual Musculoskeletal Ultrasound Forum, bringing surgeons together to exchange ideas, engage in hands-on learning activities, and shape the future of MSK ultrasound in hand surgery.

SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that it has acquired, ABBIE, a world-class gene-editing platform which can deliver genetic payloads using non-viral vectors.

The Global Ultrasound Institute has announced the completion of the largest scale ultrasound training effort for medical providers ever conducted.

In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.

The U.S. Food and Drug Administration announced updated draft guidance designed to help food facilities comply with the requirements for current good manufacturing practices and preventive controls for human food.

Blue Earth Diagnostics today announced that its optimized radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3), has been granted Transitional Pass-Through payment status for diagnostic radiopharmaceutical reimbursement by the Centers for Medicare & Medicaid Services (CMS), effective October 1, 2023.

Mirvie has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.

Carmot Therapeutics Inc. today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany.